Peter Ackerman

Biohaven Pharmaceuticals (United States) — United States

Medicine · Health Sciences

14h-index1.3kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(28), HIV Research and Treatment(18), HIV/AIDS Research and Interventions(14), Hepatitis C virus research(13), Neurofibromatosis and Schwannoma Cases(5)

Publications47 total

Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced <scp>HIV</scp> patients
Pharmacology Research & Perspectives·2025Open Access
BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies (P9-2.010)
Neurology·2025
AB0723 PHARMACOKINETICS OF ADALIMUMAB IN CYNOMOLGUS MONKEYS FOLLOWING DOSING WITH BHV-1300, A FIRST-IN-CLASS MOLECULAR DEGRADER OF IgG
Annals of the Rheumatic Diseases·2024
Population Pharmacokinetics and Exposure-Response Relationship for Temsavir Following Fostemsavir Administration in Treatment Experienced HIV Patients
2024Open Access
Supplementary Tables S1 &amp; S2 from Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues
2023Open Access
Data from Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues
2023Open Access
Supplementary Tables S1 &amp; S2 from Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues
2023Open Access
Data from Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues
2023Open Access
Table of Contents
Journal of Emergency Nursing·2022Open Access
Interprofessional In Situ Simulation to Identify Latent Safety Threats for Quality Improvement: A Single-Center Protocol Report
Journal of Emergency Nursing·2022· 5 citedOpen Access
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co‐administration
HIV Medicine·2022· 6 citedOpen Access
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection
Antiviral Therapy·2022· 1 citedOpen Access
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects
Xenobiotica·2022· 10 citedOpen Access
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Antimicrobial Agents and Chemotherapy·2022· 17 citedOpen Access
Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
Antimicrobial Agents and Chemotherapy·2022· 14 citedOpen Access
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants
HIV Research & Clinical Practice·2022· 7 citedOpen Access
834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial
Open Forum Infectious Diseases·2021· 1 citedOpen Access
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Journal of AIDS and HIV Treatment·2021· 4 citedOpen Access
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
Journal of Antimicrobial Chemotherapy·2021· 12 citedOpen Access
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
Patient·2021· 7 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Cyril Llamoso(14), Katy Moore(11), Mindy Magee(11), Max Lataillade(9), Stephanie Noviello(7), Amy Pierce(7), Andrew Clark(7), Michael D. Miller(6), Shyra J. Miller(5), Fatima Rangwala(5), Sue Kong(5), Anil G. Jegga(5), Sérgio Kaiser(5), Bruce J. Aronow(5), Silke Frahm(5), Lan Kluwe(5), Victor Mautner(5), Meena Upadhyaya(5), Margaret R. Wallace(5), Jussara Hagen(5)